PARIS and BURLINGTON, Ontario, Sept. 7 /PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), and Cedarlane, a leading supplier of high quality research reagents to the life science community, today announced that they will join forces for the distribution of Cellectis bioresearch’s research kits in Canada. The companies will pool their expertise to ensure maximum availability for the innovative Cellular Genome Positioning System (cGPS®) lines of products.
Cellectis bioresearch will be responsible for the design and production of the targeted integration kits from its cGPS® and cGPS® Custom lines. Cedarlane will be distributing these kits to research laboratories across Canada.
“Cedarlane is recognized for providing the highest quality products to the life science community,” said Luc Selig, VP Sales & Marketing at Cellectis bioresearch. “We are thus pleased to have our cGPS® research kits included in its offering. Targeted integration using meganucleases the basis of Cellectis bioresearch’s kits makes the generation of stable cell lines fast and effortless. This agreement will help us to rapidly expand the network of users for our kits.”
This partnership will offer Cellectis bioresearch a foothold in the North American research market, a major target in terms of the number of potential users. Cellectis bioresearch’s portfolio today offers over 100 product references, addressing the major needs for genome customization of the life science community.
“At Cedarlane, we seek out the highest quality life science products for our customers,” said John Course, Vice President of Cedarlane. “With the Cellectis bioresearch cGPS® lines of products, we offer our clients game changing tools.”
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The kits can be purchased online from www.cellectis-bioresearch.com. Check the website for more information.
About Cellectis
Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.
To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.
Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.
More information at www.cellectis.com
Follow Cellectis on Twitter at www.twitter.com/cellectis
About Cedarlane
CEDARLANE® (ISO 9001 & 13485) specializes in providing high quality research and diagnostic reagents to the life science community. CEDARLANE is pleased to offer one of the most extensive product listings in the World. Both a manufacturer and distributor, we offer access to a plethora of life science companies which manufacture products for all areas of research. Manufactured products include monoclonal & polyclonal antibodies, Lympholyte cell separation media, complement for tissue typing, Cellect Immunocolumns and CELLutiuons immortalized Hypothalamic, Motor Neuron, Hippocampal, Cardiac Endothelial, Oligodendrocytic, Erythroblastic and Ovarian cell lines! Delivering Today’s Innovations for the Science of Tomorrow
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
SOURCE Cellectis
